System and method for optogenetic therapy

• US 10,022,552 B2
• Filed: 07/31/2014
• Issued: 07/17/2018
• Est. Priority Date: 11/21/2012
• Status: Active Grant

• Current Assignee: Circuit Therapeutics, Inc.
• Original Assignee: Circuit Therapeutics, Inc.
• Inventors: Stahler, Greg, Mitra, Ananya, Huang, Joyce, Andersen, Dan, Arrow, Alexander K., Moore, David
• Primary Examiner(s): Gedeon, Brian T
• Application Number:
  US14/449,087
• Publication Number:
  US 20160051838A1
• Time in Patent Office: 1,447 Days
• Field of Search: None
• CPC Class Codes: A61B 17/00234 for minimally invasive surgery A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence
• CPC Class Codes: A61B 17/3403 Needle locating or guiding means guides for suture needles A61B17/0482; guiding or tracking by nuclear magnetic resonance G01R33/285
• CPC Class Codes: A61B 2017/3413 guided by ultrasound
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61K 38/168 from plants
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A61K 41/0057 Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 2205/3576 with non implanted data transmission devices, e.g. using external transmitter or receiver
• CPC Class Codes: A61M 2205/50 with microprocessors or computers
• CPC Class Codes: A61M 25/0105 Steering means as part of the catheter or advancing means; Markers for positioning systems for detection of markers A61B
• CPC Class Codes: A61M 25/0147 with movable mechanical means, e.g. pull wires
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61M 5/142 Pressure infusion, e.g. using pumps
• CPC Class Codes: A61M 5/20 Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically A61M5/142 , A61M5/46 take precedence; hypodermic projectiles F42B12/54
• CPC Class Codes: A61N 1/0551 : Spinal or peripheral nerve electrodes
• CPC Class Codes: A61N 1/3605 : Implantable neurostimulators for stimulating central or peripheral nerve system
• CPC Class Codes: A61N 1/36053 : adapted for vagal stimulation A61N1/36114 takes precedence
• CPC Class Codes: A61N 2005/0612 : using probes penetrating tissue; interstitial probes
• CPC Class Codes: A61N 2005/0626 : Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0627 : Dose monitoring systems and methods
• CPC Class Codes: A61N 2005/063 : comprising light transmitting means, e.g. optical fibres
• CPC Class Codes: A61N 2005/0631 : using crystals
• CPC Class Codes: A61N 2005/0643 : Applicators, probes irradiating specific body areas in close proximity
• CPC Class Codes: A61N 2005/0651 : Diodes
• CPC Class Codes: A61N 2005/0653 : Organic light emitting diodes
• CPC Class Codes: A61N 2005/0665 : Reflectors
• CPC Class Codes: A61N 5/0601 : Apparatus for use inside the body
• CPC Class Codes: A61N 5/062 : Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61N 5/0622 : Optical stimulation for exciting neural tissue
• CPC Class Codes: A61N 5/067 : using laser light
• CPC Class Codes: A61P 9/12 : Antihypertensives

Abstract

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

Claims

1. A method for illuminating, from within the intrathecal space of the spine of a patient, a nerve root pair that has been genetically modified to comprise light sensitive protein, comprising:

a. surgically delivering an implantable optical applicator in a compressed state through a small surgical access created between calcified structures of the spine to the intrathecal space; and

b. expanding the implantable optical applicator inside of the intrathecal space to an expanded state, the implantable optical applicator comprising a first lighting segment, a second lighting segment, and one or more biasing segments operatively coupled to one or more of the first and second lighting segments, wherein the first lighting segment is configured to illuminate a first nerve root of a selected nerve root pair while the second lighting segment is configured to illuminate a second nerve root from the selected nerve root pair, and wherein the one or more biasing segments are configured to engage a dura portion of the spine and place at least one of the first and second lighting segments in apposition to the first or second nerve root.

2. The method of claim 1, further comprising providing a first implantable light source immediately coupled to the first lighting segment of the implantable optical applicator, and a second implantable light source immediately coupled to the second lighting segment, wherein each of the light sources is operatively coupled to a power supply and a controller, such that the controller activates the first and second implantable light sources by controlling current thereto from the power supply.

3. The method of claim 2, further comprising operatively coupling the first and second light sources to the power supply and controller with a delivery segment configured to carry electrical current.

4. The method of claim 2, wherein the power supply is implantable.

5. The method of claim 4, further comprising housing the power supply and controller within a common implantable housing.

6. The method of claim 2, wherein the controller is implantable.

7. The method of claim 6, further comprising coupling the power supply to one or more implantable inductive coils configured to receive magnetic flux from a transcutaneous magnetic flux source configured to recharge the implantable power supply.

8. The method of claim 7, further comprising configuring a transcutaneous magnetic flux source to be positioned in a charging position near the skin adjacent the one or more implantable inductive coils.

9. The method of claim 8, further comprising coupling the transcutaneous magnetic flux source to a mounting device configured to retain the transcutaneous magnetic flux source in the charging position for a period of time while the patient is active.

10. The method of claim 9, wherein the mounting device is selected from the group consisting of:

a vest, a sling, a strap, a shirt, and a pant.

11. The method of claim 2, wherein the light source comprises a light emitting diode.

12. The method of claim 1, further comprising operatively coupling each of the first and second lighting segments to an implantable light source.

13. The method of claim 12, further comprising intercoupling a delivery segment between the implantable light source and the implantable optical applicator, the delivery segment configured to propagate light from the implantable light source to the implantable optical applicator where it may be distributed to the nerve root pair through the first and second lighting segments.

14. The method of claim 12, wherein the delivery segment comprises a waveguide configured to propagate substantially all light that is passed through it via total internal reflection.

15. The method of claim 12, further comprising operatively coupling the implantable light source to a power supply and controller, such that the controller activates the light source by controlling current thereto from the power supply.

16. The method of claim 15, further comprising housing the implantable light source, power supply, and controller within a common implantable housing.

17. The method of claim 15, further comprising coupling the power supply to one or more implantable inductive coils configured to receive magnetic flux from a transcutaneous magnetic flux source configured to recharge the implantable power supply.

18. The method of claim 17, further comprising providing a transcutaneous magnetic flux source configured to be positioned in a charging position near the skin adjacent the one or more implantable inductive coils.

19. The method of claim 18, further comprising coupling the transcutaneous magnetic flux source to a mounting device configured to retain the transcutaneous magnetic flux source in the charging position for a period of time while the patient is active.

20. The method of claim 19, wherein the mounting device is selected from the group consisting of:

a vest, a sling, a strap, a shirt, and a pant.

21. The method of claim 12, wherein the implantable light source comprises a light emitting diode.

22. The method of claim 1, wherein the tissue structure comprising the light sensitive protein has been genetically modified to encode an opsin protein.

23. The method of claim 22, wherein the opsin protein is an inhibitory opsin protein.

24. The method of claim 23, wherein the inhibitory opsin protein is selected from the group consisting of:

NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, Mac, Mac 3.0, Arch, and ArchT.

25. The method of claim 22, wherein the opsin protein is a stimulatory opsin protein.

26. The method of claim 23, wherein the stimulatory opsin protein is selected from the group consisting of:

ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, and ChR2-SFO.

27. The method of claim 1, further comprising aligning, in the expanded state, the first lighting segment to be immediately adjacent the first nerve root of the selected nerve root pair, and aligning, in the expanded state, the second lighting segment to be immediately adjacent the second nerve root of the selected nerve root pair, to form a deployment geometric configuration.

28. The method of claim 27, wherein at least one of the one or more biasing segments is configured to retain the deployment geometric configuration when activated.

29. The method of claim 28, further comprising operatively coupling a pullwire to at least one of the one or more biasing segments, the pullwire configured to adjust the geometry of the intercoupled implantable optical applicator to facilitate reaching the deployment geometric configuration.

30. The method of claim 1, wherein the nerve root pair is a dorsal root pair.

31. The method of claim 1, wherein the nerve root pair is a ventral root pair.